TriangleNCT00171925 · REGISTRY CONDITION SEARCH
Therapy With Zoledronic Acid in Patients With Multiple Myeloma Stage I
Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.
- Phase
- PHASE3
- Status at capture
- TERMINATED
- Registry last update
- 2012-04-11
Multiple myeloma is a disease of B-lymphocytes producing malignant plasma cells. Malignant plasma cells induce osteolytic lesions, which is characteristic for progression of multiple myeloma. It is the aim of this study to investigate whether zoledronic acid has an influence on the progression of multiple myeloma.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Who could take part
- eligibility Criteria
- Inclusion Criteria * Evidence of myeloma according to the criteria of the British Columbia Cancer Agency (for the diagnosis, 2 of the 3 criteria must be met): * Evidence of paraprotein in the serum or urine * Bone marrow infiltration with plasma cells which represent more than 10% of the nucleated cells * Radiologically, at least one osteolytic lesion * Asymptomatic patients with Stage I (Durie and Salmon) multiple myeloma Exclusion criteria: * Patients with more than one osteolytic lesion on conventional skeletal radiography * Previous treatment with bisphosphonates * bilirubin \> 2.5 mg/dl * Abnormal renal function as evidenced by: A calculated creatinine clearance \< 30 ml/minute. Creatinine clearance (CrCl) is calculated using the Cockcroft-Gault formula: * CrCl= \[140-age(years)\] x weight(kg)/\[72xserumcreatinine(mg/dL)\] X {0.85 for female patients} * Patients with other malignant diseases or severe concomitant diseases * Potentially fertile patients who are not using a reliable and appropriate method of contraception * Pregnancy or breast-feeding * Participation in another clinical study with an investigational drug within 12 weeks of study entry * Current active dental problems including infection of the teeth or jawbone (maxilla or mandibular); dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after dental procedures. * Recent (within 6 weeks) or planned dental or jaw surgery (e.g.. extraction, implants) Other protocol-defined inclusion and exclusion criteria may apply.
- healthy Volunteers
- false
- minimum Age
- 18 Years
- sex
- ALL
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- arm Groups
- description
- Participants received intravenous infusion of Zoledronic acid every 4 weeks for 48 weeks, and calcium and Vitamin D daily.
- intervention Names
- Drug: Zoledronic acid
- Dietary Supplement: Calcium / Vitamin D
- label
- Zoledronic acid (ZOL446)
- type
- EXPERIMENTAL
- description
- No treatment with study medication.
- label
- Control
- type
- NO_INTERVENTION
- interventions
- arm Group Labels
- Zoledronic acid (ZOL446)
- description
- Zoledronic acid administered via normal saline intravenous infusion (over 15 minutes) every 4 weeks. Dosage was according to calculated creatinine clearance: patients with baseline creatinine clearance \> 60 ml/min received 4 mg; for patients with mild to moderate renal impairment, doses were calculated to achieve the same AUC as that achieved in patients with creatinine clearance of 75 ml/min, assuming target AUC of 0.66 (mg\*hr/l).
- name
- Zoledronic acid
- type
- DRUG
- arm Group Labels
- Zoledronic acid (ZOL446)
- description
- Patients on zoledronic acid received 500 mg calcium and 400-500 IU vitamin D combination tablet daily.
- name
- Calcium / Vitamin D
- type
- DIETARY_SUPPLEMENT
Study design
- allocation
- RANDOMIZED
- intervention Model
- PARALLEL
- masking Info
- masking
- NONE
- primary Purpose
- TREATMENT
Enrollment
- count
- 143
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- Progression-free survival was defined as time from date of randomization to death from any cause or one of the following events: * progression to stage II or III according to Salmon \& Durie classification * skeletal related events (pathologic fracture, initiation of radiotherapy or surgery on bone, spinal cord compression or hypercalcemia) * unequivocal progression of osteolytic lesions (at least a 20% increase in the largest diameter of one existing osteolytic lesion which is measured in at least one dimension as 20 mm with conventional techniques), determined radiologically.
- measure
- Days of Progression Free Survival
- time Frame
- 48 months
- secondary Outcomes
- description
- Number of patients with progression by individual criteria consisting of Progression of disease overall, Skeletal-related events (including pathological fracture, initiation of radiotherapy or surgery on bone, spinal cord compression or Hypercalcemia), Progression to stage II or III according to Salmon \& Durie classification, and unequivocal progression of osteolytic lesion. Patients are counted separately for every type of progression, but only once for Overall Progression.
- measure
- Number of Patients With Progression by Individual Criteria
- time Frame
- 48 months
- description
- * Pathologic fracture: bone fractures that occur spontaneously or from trivial trauma. New vertebral compression fracture defined as a decrease in vertebral height of 25% from baseline * Spinal cord compression: the impingement of tumor on the spinal cord confirmed by radiography * Bone Radiotherapy: Bone irradiation to palliate painful lesions, treat or prevent pathologic fractures or spinal cord compression * Surgery on bone: surgical procedures performed to set, stabilize or prevent pathologic fractures or areas of spinal cord compression * Hypercalcemia: Corrected serum calcium ≥ 12.0 mg/dl
- measure
- The Number of Participants With the Development of Skeletal Complications
- time Frame
- 48 months
Full study description
- brief Summary
- Multiple myeloma is a disease of B-lymphocytes producing malignant plasma cells. Malignant plasma cells induce osteolytic lesions, which is characteristic for progression of multiple myeloma. It is the aim of this study to investigate whether zoledronic acid has an influence on the progression of multiple myeloma.
Source references
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-1336d216cbd1bbff780dac70
- edge id
- nct-edge-dc18193f61126f0a86e6
- requested nct id
- NCT00171925
- primary nct id
- NCT00171925
- source kind
- ctgov_condition_query
- source record id
- Source null
- source file sha256
- 2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
- payload sha256
- c108202e84e86e6ab61bf5efbe59998e71748bdc7268457c565e20b1efeca3e2
- payload
- clinical indication matching status
- condition_index_match_asserted_by_registry_not_reviewed
- end exclusive
- true
- id
- nct-edge-dc18193f61126f0a86e6
- link basis
- returned_by_explicit_condition_and_posted_results_filter_query
- nct id
- NCT00171925
- occurrences
- context exact
- NCT00171925
- end
- 11
- exact text
- NCT00171925
- start
- 0
- offset unit
- unicode_code_points
- query cond
- Plasma Cell Neoplasms
- query disease state id
- ds-plasma-cell-neoplasms
- source file
- /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
- source file sha256
- 2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
- source json pointer
- /studies/85/protocolSection/identificationModule/nctId
- source kind
- ctgov_condition_query
- source record id
- Source null
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 95b4c3af4afe935dbe5f9f1b9ade56c82c3b6d44d181d69d6b2e50f7004a436a
Preserved source evidence · Not medical advice